Tavneos (avacopan) is a medication available in a 10mg dosage form. It is an orally administered, selective C5a receptor inhibitor [1].
What is Tavneos used for?
Tavneos is indicated for the treatment of severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis in adult patients [1]. ANCA-associated vasculitis is a group of rare autoimmune diseases that cause inflammation of small blood vessels [2].
How does Tavneos work?
Tavneos works by inhibiting the complement component 5a (C5a) receptor. In ANCA-associated vasculitis, the complement system can be activated, leading to the production of C5a. C5a then binds to the C5a receptor on neutrophils, triggering their activation and subsequent attack on small blood vessels. By blocking this receptor, Tavneos prevents neutrophil activation and reduces inflammation [1].
What are the potential side effects of Tavneos?
The most common side effects reported in clinical trials include diarrhea, nausea, upper abdominal pain, vomiting, headache, and influenza [1].
What is the patent status of Tavneos?
The patent landscape for Tavneos can be complex and is subject to change. Information on specific patent expirations and any ongoing legal challenges can be found through resources that track drug patents [3].
Who makes Tavneos?
Tavneos is manufactured by ChemoCentryx, Inc., which is a subsidiary of Amgen [1].
How does Tavneos compare to other treatments for ANCA-associated vasculitis?
Tavneos is used in combination with standard therapy, typically rituximab or cyclophosphamide, which are immunosuppressive agents [1]. The addition of Tavneos to standard therapy has demonstrated efficacy in achieving remission and maintaining remission in patients with severe active ANCA-associated vasculitis [1].
What is the clinical data supporting Tavneos?
The efficacy and safety of Tavneos were established in a randomized, double-blind, placebo-controlled trial. In this trial, patients treated with Tavneos plus standard therapy showed higher rates of remission compared to those treated with placebo plus standard therapy [1].